康艾注射液联合TP方案化疗对非小细胞肺癌患者免疫功能及生活质量的影响

Effect of Kang’ai Injection Combined with TP Regimen Chemotherapy on Immune Function and Quality of Life in Nonsmall Cell Lung Cancer Patients

目的:研究康艾注射液联合TP方案化疗对非小细胞肺癌(NSCLC)患者免疫功能及生活质量的影响。方法:选取2019年11月—2023年2月于盐城市中医院治疗的110例NSCLC患者。依据信封法分为对照组(n=54)和观察组(n=56),对照组按照美国国家癌症综合网(NCCN)指南标准进行TP方案化疗,观察组在对照组基础上给予康艾注射液治疗。比较两组疗效、肿瘤标志物、免疫球蛋白、生活质量及不良反应发生率。结果:观察组客观缓解率为87.50%,高于对照组的68.52%,差异有统计学意义(P<0.05)。治疗后两组癌胚抗原(CEA)、血管内皮生长因子(VEGF)及神经元特异性烯醇化酶(NSE)均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组免疫球蛋白G(IgG)、免疫球蛋白M(IgM)及免疫球蛋白A(IgA)高于治疗前,对照组IgG及IgA低于治疗前,且观察组IgG、IgM、IgA均高于对照组,差异有统计学意义(P<0.05)。治疗后,两组健康调查简表(SF-36)评分、卡氏功能状态(KPS)评分均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。观察组不良反应总发生率为17.86%,高于对照组的11.11%,差异无统计学意义(P>0.05)。结论:NSCLC患者采用康艾注射液联合TP方案化疗治疗的效果较好,能有效降低患者肿瘤标志物水平,提高免疫力及生活质量。

Objective:To study the effect of Kang’ai Injection combined with the TP regimen chemotherapy on immune function and quality of life in patients with non-small cell lung cancer(NSCLC).Method:A total of 110 NSCLC patients treated in Yancheng Traditional Chinese Medicine Hospital from November 2019 to February 2023 were selected.According to envelope method,they were divided into control group(n=54)and observation group(n=56).The control group received TP regimen chemotherapy according to National Comprehensive Cancer Network(NCCN)guidelines,and the observation group received Kang’ai Injection on the basis of the control group.The efficacy,tumor markers,immunoglobulin,quality of life and incidence of adverse reactions were compared between the two groups.Result:The objective remission rate of the observation group was 87.50%,which was higher than 68.52%of the control group,the difference was statistically significant(P<0.05).Carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF)and neuronal specific enolase(NSE)in two groups after treatment were lower than those before treatment,and observation group were lower than those in control group,the differences were statistically significant(P<0.05).After treatment,immunoglobulin G(IgG),immunoglobulin M(IgM)and immunoglobulin A(IgA)in the observation group were higher than those before treatment,IgG and IgA in the control group were lower than those before treatment,and IgG,IgM and IgA in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).After treatment,the MOS item short from health survey(SF-36)score and Karnofsky performance status(KPS)score of two groups were higher than before treatment,and the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was 17.86%,which was higher than 11.11%in the control group,and the difference was not statistically significant(P>0.05).Conclusion:NSCLC patients treated with Kang’ai Injection combined with TP regimen chemotherapy has a good effect,which can effectively reduce the level of tumor markers in patients,improve immunity and quality of life.